Vaccine leadership is possible
Morrison & Cole, 10-13-2020, J. Stephen Morrisonsenior vice president here at the Center for Strategic and International Studies, CSIS & Congressman Tom Cole, Republican of Oklahoma https://www.csis.org/analysis/online-event-conversation-congressman-tom-cole, "Online Event: A Conversation with Congressman Tom Cole," No Publication (ermo/sms, Acc:6-20-2022)
J. Stephen Morrison: Thank you. I want to ask you about the international domain and U.S. leadership in the international domain. There’s a couple of big issues there. You know, the global health security agenda has been an instrument in building capacity in low-income countries that are vulnerable. That was – that came about around the same time as Ebola. It got turbo charged with the supplemental. But there’s a question of sustaining that as a way of building defenses and preparedness in those countries that are very vulnerable.
There’s also the issue of the vaccine facility, to bring vaccines to low and middle-income countries that may really struggle to get that. And we have the COVAX facility led by CEPI and Gavi, Gavi playing the procurement and distribution role. U.S. has chosen not to be part of the COVAX facility. The door is still open. That can be changed. Congress can play a role there. And related to that is a question of WHO reform. Obviously, the president has chosen to terminate membership in WHO. That has been a controversial issue. We need to be thinking about what is the future of attempting to reconnect with WHO under what basis. We have the Independent Panel on Preparedness and Response that’s underway, an international group, which is charged with looking at these issues. And the U.S. has supported that panel.
Tell us your thoughts around what the U.S. leadership role should be in the international domain, particularly with reference to low and lower-middle income countries in this next phase.
Rep. Tom Cole: Well, I start with a belief that – you know, I’m a big believer in enlightened self-interest. I think some of the best things we’ve done in the country – you know, whether it’s PEPFAR or whether it’s NATO – they’re very different types of efforts, obviously. But the reality is, helping others to help yourself is pretty smart. And where disease is concerned, there is no border that will protect you. So, we need to be engaged globally on the health-care front. I actually toured yesterday – or, excuse me – Monday, I think, a biomedical facility in Maryland where they manufacture a whole variety of products. But two of the most interesting are things that, number one, are rapidly test – you can use them routinely, but they have surge capacity. So, we would never have this testing problem if we built these type of things and grouped them in appropriate places.
The other thing is that a smaller test, they argue, you could spread all over the world that could test unique things that we would – we would, you know, pick it up. Look, as I said, this is actually – you know, we had Ebola in Africa. We had one guy get to Dallas that was carrying the disease. You want to fight Ebola in West Africa or west Dallas? I know where I would pick. So, we need to be very aggressive. And a lot of the countries don’t have much health-care infrastructure. It’s not that they’re not fine, but strengthening their infrastructure strengthens our protection. It’s just that simple. I mean, we live in a world where disease can move with extraordinary speed.